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Summary 
We have previously postulated that donor cell chimerism in 
organ transplantation is needed to attain a tolerant state. Here 
we show that donor cell chimerism can be augmented in organ 
recipients if they are infused perioperatively with 3 x 10' per 
kg of unmodified donor bone marrow cells and are kept on a 
conventional immunosuppressive regimen of tacrolimus 
(FK506) and prednisolone. 
36 patients took part, of whom the first 18 patients have 
good transplanted kidney (n = 10), liver (n = 7), and heart 
(n = 7) function when followed up between 4 and 16 months. 
All patients are well. We found persistent multilineage 
leucocyte chimerism in blood of 17 recipients by flow 
cytometry and peR techniques to detect donor alleles or Y 
chromosomes in female reCipients of male organs. The use of 
the 5-antigen HLA matched same sex donor precluded 
detection of chimerism in one patient. 
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Introduction 
We have hypothesised that the migration of donor 
leucocytes from organ transplants and the persistence of 
these cells in recipient tissues explains allograft acceptance, 
and1,2 is the first stage in the development of donor-specific 
tolerance, We augmented the leucocyte load from the donor 
by giving a perioperative infusion of unmodified bone 
marrow to 36 patients, We report the follow-up status of the 
first 18 patients: 10 kidney recipients, 7 liver recipients, and 
1 heart recipient. These patients included 3 diabetics who 
were also given pancreatic islets intraportally, and a liver 
recipient with a positive lymphocytotoxic crossmatch. 
Patients and methods 
Patients 
18 followed-up patients treated between December 1992, and 
December 1993, were aged 20 to 63 years (mean 46, [SD 13'2]) and 
included 3 diabetics who had been insulin dependent (55-65 
units/day) for 18-37 years. The cadaver donors were aged between 
8-60 years (mean 31, [SD 14'8]), were ABO identical with their 
recipients, and had HLA antigen mismatches (ofa possible 6) of3·8 
(1'7),5'7 (0'5), and 6·0 for the kidney, liver, and heart recipients, 
respectively. No patient had complete HLA compatibility. Patient 
6 (a liver recipient) had a positive Iymphocytotoxic crossmatch. 9 
kidney and 17 liver recipients who did not receive bone marrow 
because permission for bone removal from the cadaver was denied 
were used as controls. 
Bone marrow preparation* 
Thoracolumbar vertebrae from the donors were excised, 
separated, and transported at room temperature in Dulbecco's 
Modified Eagle Medium (Gibco, Grand Island, N Y USA). Bone 
marrow cells from the chipped-off cancellous bone were passively 
released into the processing medium, filtered, and centrifuged at 
300 g for 11 min. The pellet was placed in suspension medium and 
the cell number and viability by trypan blue exclusion were 
determined. More suspension medium was added to dilute the cells 
to 2 x 107/mL, and the final product was refrigerated at 4·C until 
infusion. 
When needed, an aliquot of cell suspension containing 3 x 10" 
cells/kg, was removed and centrifuged. The pellet was resuspended 
in 200 mL of the same suspension fluid and infused intravenously 
over 20 min, 2-12 hours after revascularisation of the whole organ 
grafts. Samples of the final infusate were retained for dose 
confirmation, progenitor cell assays, microbial testing, and flow 
cytometric analysis. 
Pancreatic islets 
Islet isolation was done with a modified automated method.' 
5-7 x 105-1-5 x 106 islets (3·2 x 105-8.4 x 105 islet equivalents) from 
the organ donor were infused into the portal vein of 1 liver and 2 
kidney recipients. 
*Details of processing and suspension media are kept at The Lancet. 
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Figure 1: Immunosuppression and MLR responses to Irradiated 
donor and third-party cells, and donor cell chimerism by flow 
cytometry for case 18 In the first 6 months after heart-bone 
marrow transplantation_ 
Immunosuppression 
Routine immunosuppression with Tacrolimus (FK506) and 
prednisone 4,S was started after organ revascularisation. Plasma 
trough concentrations of Tacrolimlnus were targeted to 1·5-2·0 
ng/mL in the first postoperative month, and 0·5-1·2 ng/mL 
thereafter with adjustments guided by side effects and/or rejection. 
One gram methylprednisolone (1 g) was given intraoperatively, 
Patient Allograft POD Graft Function' Immunosuppresslont 
Bilirubin Creatinine Tacrolimius/steroid 
(mg/dl) (mg/dl) (mg per day) 
1 Liver 125 05 30;0 
2 Liver + islets 198 03 10; 5 
3 Liver 232 08 2;0 
4 Liver 251 05 6;0 
liver 271 07 8;0 
6 liver 294 OA 6;05 
7 Liver 389 10 2; 0 
8 Kidney 119 11 36; 10 
9 Kidney 161 11 20; 125 
10 Kidney 177 11 10; 25 
11 Kidney 243 16 18;25 
12 Kidney + Islets 292 27 9; 15 
13 Kidney + Islets 294 lA 24; 25 
14 Kidney 348 18 6;0 
15 Kidney 351 18 18; 10 
16 Kidney 432 12 4;0 
17 Kidney 484 17 9:0 
18 Heart 199 Good cardiac function 8; 15 
followed by a 5-day rapidly tapered prednisone cycle, decreasing 
from 200 mg to 20 mg by day 64,s except for the heart recipient 
whose steroid induction was lighter (figure 1). This patient also was 
given azathioprine for the first 26 days. Drug weaning for the other 
patients was individually assessed. Azathioprine (n = 3) and OKT3 
(n = 1) were reserved for rejection that was not responsive to dose 
adjustments of Tacrolimus and/or prednisone. 
Determination of chimerism 
Probes that detected donor leucocyte HLA antigens (chromosome 
6) in venous blood were routinely used. Additionally, 4 female 
recipients of male organs had chimerism detected by Y 
chromosome in situ hybridisation. Multiple technologies were 
used to study both the chromosome 6 and the Y chromosome.' 
Monoclonal antibodies 
Primary mouse-anti-human monoclonal antibodies (mAb) 
directed against HLA class I or II epitopes were labelled by 
fluorescein isothiocyanate (FITC)-conjugated goat-anti-mouse 
secondary antibodies. Their appropriate specificity and optimal 
dilution was confirmed by staining donor splenocytes and recipient 
pretransplant peripheral blood cells. Leucocyte lineages were 
determined with lineage-specific PE or FITC-conjugated mouse-
anti-human mAbs. Isotype-matched irrelevant monoclonal 
antibodies were used as negative controls. 
We sorted and identified donor cells with anti-HLA class I mAb 
by fluorescent activated cell sorter (FACS) analysis. The reliable 
detection threshold was 0,5%. Donor and recipient leucocyte 
lineages were determined in the unsorted cell population and also 
in sorted donor (positive) and recipient (negative) cells with 
two-colour immunofluorescence staining and re-analysis by 
FACS. In cross-control experiments, the DNA was extracted from 
sorted cells, and the accuracy of their sorting into donor and 
recipient populations was confirmed by blind examination with 
polymerase chain reaction (PCR). 
In-situ hybridisation 
Cytospin preparations of peripheral blood mononuclear cells 
(PBMC) were hybridised with probes directed against X or Y 
chromosome at 37°C for at least 30 min. We labelled X-specific 
probe with digoxigenin and conjugated the Y -specific probe with 
biotin. The probes were localised by rhodamine-conjugated 
anti-digoxigenin and FITC-conjugated avidin. Nuclei were 
counterstained with 4, 6-diamidino-2-phenylindone and viewed 
using a Nikon Optiphot II microscope fitted with a triple band pass 
filter. Cytospin and flow cytometry were both used in selected 
HvG GvH Donor-specillc Detection of donor celli 
(POD) (POD) MLR response§ POD' FACS (%) PCR (%)(POD) 
None None 111 (96) 96 46 + 
15; 86 None 80 (131) 127 <05 + 
7;22 None 31 (178) 204 18 + 
None 54 14 (161) 146 19 + 
None 21;74 107 (236) 236 <05 + 
33 None 30 (280) 252 16 + 
24 None 28 (368) 265 NF + 
None None 80 (93) 93 09 + 
47 None 46 (105) 105 23 + 
None None 28 (134) NF NF 
None Npone 65 (194) 183 <05 + 
14;41; None 44 (257) 204 13 + 
55;230 
16 None 42 (275) 276 30 + 
None None 18 (316) 316 27 NF 
16; 263 None 13 (323) 232 NF + 
16 None 28 (68) 315 <05 + 
None None NF 367 NF + 
12-40' None 119 (149) 149 6·4 + 
POD ~ Post operative day; HvG ~ host versus graft; GvH ~ graft versus host; MLR ~ mixed lymphocyte reaction; NF ~ not feasible as no adequate donor spleen cells or cross reactive antibodies. 
'c peptide for patients 2, 12, and 13 was 002. OA4, and 011 pmol/mL respectively. tlmuran was given to patients 12 and 13 at 75 mg per day. §Percentage of donor specific MLR response 
compared with the third party on the last sample tested. 
Table 1: Profile of graft function, Immunosuppression and In vitro Immune status of patients with donor bone marrow and organ 
transplantation 
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patients to determine the congruence of chromosome 6 and Y 
chromosome studies. 
Polymerase chain reaction (PCR) 
Previous techniques using PCR to detect spontaneous 
microchimerism'·l.& were feasible in 16 of the 18 cases. It can 
reliably detect one donor cell within 10000 recipient cells. In 15 
cases, we used probes directed against class II or the Y 
chromosome. DNA was amplified and resolved by electrophoresis 
on an agarose gel. After Southern blotting, the membrane was 
hybridised with a specific radiolabeled probe, exposed to film and 
developed. In 1 kidney and bone marrow recipient, who was a 
perfect DR (c1ass II) match with the donor, (case 16, Table I and 2), 
primers specific for the donor HLA class I (A29) allele were used. 
peR was not technically feasible in the other 2 cases. 
Persistent circulating DNA was much easier to find than in our 
earlier studies"· (Rudert WA, Kocova M, Rao AS, Trucco M, 
unpublished) and was quantitated with competitive PCR (cPCR) 
in 2 female patients who received a male liver (case 4) or kidney 
(Case 17). The process involved the co-amplification of the sample 
being tested (the target template) together with an artificial DNA 
fragment the "competitor"-distinguishing the 2 amplification 
products by a size difference caused by the addition of a 'pacer 
DNA segment in the competitor. By adding known concentrations 
of competitor DNA to a fixed amount of target template before 
amplification, we derived the equivalent molar amount of donor 
genomic DNA in the target sample by matching parallel readings 
and expressing them as DNA genomic copies. 
Immunological testing 
The immunological status of the patient pre-transplantation and 
post-transplantation was determined in vitro by the response of 
patient's PBMC to conconavalin A and phytohaemagluttinen 
(PHA) mitogens and recall antigen, mixed lymphocyte reaction 
(MLR), and cell-mediated Iymphocytotoxicity (CML) . The 
human MLR cultures were done using gamma-irradiated donor 
splenocytes and third-party PBMC as stimulators (5 x 10' cells), 
and with recipient PBMC as responders (5 x 10· cells). The cells 
were cultured for 6 days in 5% CO, in air; for the final 20 hours 
37 kbq of [,H)-thymidine was added to each well. We determined 
'H thymidine incorporation by liquid scintillation counting. For 
CML, PH A-activated "Cr-Iabeled donor splenocytes and third-
party PBMC were used as targets [T) to assess the effector [EJ 
functions of 5-6 day MLR-cultured recipient'S PBMC. We used 
various E:T ratios, ranging from 10:1 to 40:1. 
Reaulta 
Clinical course 
The bone marrow infusions were uneventful, and 
convalescence was rapid . The liver-islet recipient 
developed Epstein-Barr virus-associated lympho-
proliferative disease (LPD) limited to the colon on 
postoperative day 71 which spontaneously stopped when 
immunosuppression was reduced (Case 2, table 1). All 
whole organs functioned well after follow-ups of 4 to 16 
months. Postoperative C-peptide activity was initially 
present in all 3 diabetic recipients of pancreatic islets and 
was high enough in 2 recipients to be insulin-free when 
Tacrolimus and prednisone (which are both diabetogenic) 
were stopped. However, the C-peptide diminished below 
this threshold in 2 of the 3 patients and was at the borderline 
in the third (0 '44 pmol/mL, table 1). All 3 patients remain 
insulin dependent. 
Rejection 
Half the patients developed . ejection between 7 and 263 
days postoperatively (table 1), which was treated with dose 
adjustments ofTacrolimus and prednisone (n = 6), addition 
of azathioprine (n = 3), or administration of OKT3. One of 
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Figure 2: In situ hybrldlsatlon for Y chromosome (arrows) In 
leucocytes obtained from a female recipient of a male organ 
(calle 11), 120 days after kJdney-bone marrow transplantation 
(x 1000) 
the 3 late rejections (table 1,86 days) occurred 9 days after 
discontinuing immunosuppression for the treatment of 
colonic LPD in a liver-islet recipient. However, the only 
cause for rejections at 230 and 263 days in kidney recipients 
was insufficient immunosuppression. 
Graft-versus-host disease (GVHD) 
Histopathological grade II skin GVHD found on the trunk 
of one liver recipient was treated by briefly increasing 
the prednisone dose from 7·5 to 15 mg/day. In another 
patient a Grade I lesion on the pre-tibial skin resolved 
spontaneously. 
Chimerism 
Circulating donor cells were detected in all patients 
except for a male recipient of a male organ (Case 10) in 
whom detection was not technically feasible (table 1). 
Consequen tly, the chimerism analysis was limited to 17 
patients. 
In 14 cases in which appropriate monoclonal antibodies 
were available, 12 (85 '7% ) had 0 '6-5% cirCUlating donor 
cells in January, 1994, and at the latest examination, 10 
('11 %) had 0.9-6'4% chimerism (table 1). The other 4 who 
had no detectable cells with flow cytometry did have the 
continued presence of donor DNA when PCR methods 
were used. In the other 3 recipients chimerism was easily 
demonstrated with Y chromosome detection (figure 2), 
table 1) or by PCR in all 3 (table 2). 
The donor cells quantitated with flow cytometry were 
multilineage. We verified this observation in a liver-islet 
recipient who had 1'7% chimerism 82 days post-
transplantation, (case 2). Donor cells were sorted, restained 
for the lineage markers, and reanalysed by FACS. The 
presence of T, B, natural killer, and progenitor (CD33 or 
PatIont AlloCreft POD FACS Y chrom_. detectloa 
peR cPeR In situ 
hybridi.atioo 
Liver 146' 1-9'1\ + 10% 02'1\ 
11 Kidney 183) <0-5'1\ + NT 10% 
15 Kidney 232 NF + NT 14% 
17 Kidney 367 NF + 0-5% 02'1\ 
'sample fOl cPeR and in situ hybridisalioo was obtained on POD 128; tthe sample fOl in situ 
hybridizatioo was obtained 00 POD 120_ 
NT = oot tested; NF = oot feasible as cross reactive antibodies 
Table 2: DetecUon of chimerism In 4 female recipients of male 
organs 
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Figure 3: MLR of a kidney-bone marrow recipient (case 14) 
Mean (SO) of ['Hlthymidine incorporation 
CD34) cells was confirmed. As a secondary control in 
patient 2 and patient 11 the cells sorted as donor and 
recipient were accurately identified as such by blind study 
with PCR. 
Table 2 shows 4 male to female transplant cases. Case 11, 
had 1·9% chimerism with HLA allele detection (FACS 
analysis) compared with 1 % by the Y chromosome marker 
method. However, 63 days later less than 0'5% of donor 
cells were detected by FACS. Patient 4 had quantitative 
measurement by F ACS as well as of the donor genome with 
cPCR. We demonstrated chimerism in patient 15 with 
qualitative PCR plus direct demonstration of 1·4% of cells 
with Y chromosome on day 232 (table 2). Similarly, Y 
chromosomes were found on day 367 in the cells of patient 
17. 
PCR detected the highest yield of chimerism (16 of 18 
cases). In one recipient a perfect DR match precluded use of 
a class II oligonucleotide (case 16, table 1). Donor cells were 
detected up to 315 days with primers specific for the HLA 
class I allele, A29. Donor DNA in the other 15 patients who 
were PCR positive was found with a heterotopic HLA class 
II allele or the SRY region of the Y chromosome until 367 
days. 
In 2 patients whose Y chromosome was the chimeric 
marker, donor genome was estimated to be 1·0% ofthe total 
DNA at 128 (case 4) andO'5% at 367 days (case 17, table 2). 
KIdney 
Without bone 
marrow 
With bone 
marrow 
Uver 
Without bone 
marrow 
With bone 
marrow 
n 
9 
10 
17 
Survive 
>100 
days 
8 (89%) 
10 (100%) 
13 (765%)* 
7 (100%) 
Graft function (SD) 
Bilirubin Creatinine 
(mg/dL) (mg/dL) 
05 (02) 22 (09) 
05(0 2) 16 (05) 
09 (04) 15 (08) 
07 (0 3) 14(04) 
Chlme~Km 
PCR 
(positive/ 
total 
3/5 
8/8 
6/11 
7/7 
Donor· 
speclflc 
hypo. 
reactivity 
1/5 
5/7 
1/9 
4/7 
*of the 17 patients, 4 died within 17-40 days after transplantation due to various causes; 
after initial follow-up one patient opted to drop out of the study whereas one patient was 
re·transplanted on POD 21 due to primary graft failure. 
Table 3: Responses of whole organ allograft recipients with and 
without donor bone marrow augmentation 
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Patient 17 was a kidney reCIpient, and donor DNA 
gradually disappeared from the blood during the first 2 
months but then increased steadily throughout the rest of 
the first postoperative year.9 Chimerism was estimated to 
be 1000 times more than that seen in any of the chronically 
surviving microchimeric kidney recipients.s 
Immune monitoring 
The lack of donor spleen cells precluded in vitro studies in 
case 17. In cases 10 and 16 a low donor-specific response 
preceding and following transplantation meant that 
meaningful observations were not possible. (Table 1, 
footnote). Samples from the other patients showed donor-
specific hyporeactivity in 60% (table 1), which could be 
seen as early as 40 to 50 days postoperatively (figure 3). 
The remaining 6 patients (cases 1, 2, 5, 8, 11, and 18) 
maintained vigorous proliferative responses against the 
donor and panel cells (65-119 % of third party) up to the 
latest sample tested (3 livers, 2 kidneys, and the heart) (table 
1). Only 1 patient (case 2) had rejection beyond 40 days. The 
kidney recipient (case 11) who had pre- and post-transplant 
donor and third party-specific cytotoxic activity lost the 
donor-specific killing in CML assays while maintaining 
third-party killing. There were no other examples of either 
donor or third-party specific cytotoxic activity before or 
after transplantation. 
Control patients 
Table 3 shows survival in the control kidney and liver 
recipients. The median time to first rejection was 27 days in 
the 21 control patients who survived through the study 
compared with 33 days in the marrow-treated patients (not 
significant, p = 0·547 by Mantel-Cox test). Rejection-free 
interval and cumulative incidence of rejection were the 
same in the study and the control groups (Kaplan-Meier 
method). Histopathologically, the rejections were not 
distinguishable in the control and marrow-augmented 
groups. 
After transplantation, spontaneous chimerism was not 
detectable by FACS in the control groups, but was found 
with PCR in 9/16 (56%) of cases where analysis was feasible 
(6/11 in the livers and 3/5 in the kidneys). Donor-specific 
hypo reactivity was observed at 4 months in 2/14 (14'3%) of 
the controls in which testing was feasible versus 9/14 
(64'3%) of the bone marrow group at about the same time 
(table 3). 
Discussion 
Tolerance induction with live donor leucocytes became the 
bedrock of modern transplantation after its first description 
in mice. 9 Pioneer efforts to use tolerance for whole organ 
transplantation with bone marrow10 or by using donor 
specific blood transfusion" were hampered by several 
factors: the assumption that the infused cells have a 
transient survival unless there is preconditioning; fear that 
the chimeric cells would cause GVHD; and lack of 
information about the appropriate timing of leucocyte 
administration. Consequently, previous leucocyte 
augmentation trials have failed outright, yielded equivocal 
results, or been inapplicable to cadaveric transplantation. 
11-16 Our discovery that chimerism is a naturally occurring 
event after whole organ transplantation has enabled us to 
give MHC-incompatible bone marrow safely without 
recipient preparation or deviation from standard practices 
of immunosuppression. 
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Unaltered bone marrow infusion without recipient 
preconditioning did not cause perceptible harm to the first 
18 patients. The transient GVHD observed in 2 of 7 liver 
recipients was clinically insignificant and disappeared with 
little or no change in therapy. The true incidence of these 
skin manifestations of GVHD in conventionally treated 
liver or other organ recipients is not available for 
comparison, because the self-resolving rashes have been 
incorrectly attributed to transient allergies and not 
systematically biopsied or treated! 
The unusually high 4-month mortality of 11 % and 24% 
for the control kidney and liver recipients, respectively, 
may have been an artifact of case selection. The severity of 
rejection in the marrow versus contemporaneous non-
marrow cohorts was not qualitatively or quantatively 
different. The average graft function at 4 months was the 
same in the culled (by mortality) control and in unculled 
bone marrow liver groups. The function of the transplanted 
kidneys in the control patients was poorer than in the 
experimental series. 
The most striking clinical observation was a 
convalescence pattern of a bidirectional immunological 
confrontation most clearly defined by rejection (but also by 
GVHD) that was followed by a successful outcome. These 
events, which have long been inexplicable, were seen 30 
years ago in the first kidney recipients treated with 
azathioprine and prednisoneP The same postoperative 
events are seen with all transplanted organs and with all 
immunosuppressive regimens. This characteristic 
sequence of crisis and recovery is the reason for our original 
suspicion that persistent chimerism must be present in 
successful cases. 1 When chimerism was found,I,2,6,8 the 
logical next step was to augment it. Our expectation was 
that the cyclic events of recovery would be much the same as 
in historical cases but with the ultimate achievement of 
denser chimerism. 
The chimerism with adjuvant bone marrow was 1000-
fold greater than that found in our previously reported 
long-term surviving kidney8 and liver recipients/,6 and 
greatly exceeded the trace chimerism in the control patients 
at 4 months. Rejection in 9 (50%) of the bone marrow 
augmented recipients and minor GVHD in 2 (11 'Yo) in the 
presence of this sustained chimerism underscores our 
earlier warning that chimerism is not synonymous with 
tolerance, but is a necessary condition for its 
attainment.1,2.18 
Tests of immune reactivity in vitro may help in deciding 
how long a patient should be kept on continuous 
suppression. More than half of our test patients have 
evidence of evolving donor specific nonreactivity by in vitro 
testing compared with 14% of the non-marrow controls, 
However all patients still receive immunosuppressive 
therapy and withdrawal of these agents is not planned until 
at least 18 months after the operation. While the eventual 
effect of the augmented chimerism remains speculative, we 
believe that it will allow our patients to aspire to an eventual 
drug-free state. Evidence of realistically achieving our 
Vol 344 • July 16, 1994 
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objective is reinforced by reports of spontaneously chimeric 
liver recipients who have not had immunosuppression for 
many years,2,19 and smaller numbers of kidney recipients for 
whom deliberate drug withdrawal is thought to be far more 
dangerous. 18 
Aided by Project Grant No DK 29961 from the National Insitutes of 
Health, Bethesda, Maryland. 
Referenc .. 
Starzl TE, Demetris AJ, Murase N, IIdstad S, Ricordi C, Trucco M. 
Cen migration, chimerism, and graft acceptance. Lancet 1992; 339: 
1579, 
2 Starzl TE, Demetris AJ, Trucco M, et al. Cen migration and 
chimerism after whole organ transplantation. The basis of graft 
acceptance. Hepatology 1993; 17: 1127. 
3 Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated 
method for isolation of human pancreatic islets. Diabetes 1988; 37: 
413-20. 
4 Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. 
FK 506 for human liver, kidney and pancreas transplantation. Lancet 
1989; ii: 1000. 
5 Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S. 
Selected topics on FK 506: With special references to rescue of 
extrahepatic whole organ grafts, transplantation of "forbidden 
organs"} side effects, mechanisms, and practical pharmacokinetics. 
Transplant Proc 1991; 23: 914-19. 
6 Starzl TE, Demetris AJ, Trucco M, et at. Systemic chimerism in 
human female recipients of male livers. Lancet 1992; 340: 876-77. 
7 Kocova M, Siegel SF, Wenger SL, Lee PA, Trucco M. Detection of Y 
chromosome sequences in Turner's syndrome by Southern blot 
analysis of amplified DNA. Lancet 1993; 342: 140-43. 
8 Starzl TE, Demetris AJ, Trucco, et a1. Chimerism and donor specific 
nonreactivity 27 to 29 years after kidney allotransplantation. 
Transplantation 1993; 55: 1272. 
9 Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of 
foreign cells. Nature 1953; 172: 603-06. 
10 Monaco AP, Clark AW, Brown RW: Active enhancement ofa human 
cadaver renal allograft with ALS and donor bone marrow: Case report 
of an intitial attempt. Surgery 1976; 79: 384-92. 
11 Salvatierra 0 J r, Melzer J, Potter D, et at. A seven-year experience 
with donor-specific blood transfusions. Results and considerations for 
maximum efficacy, Transplantation 1985; 40: 654-59. 
12 Najarian JS, Ferguson RM, Sutherland DER, et at. Fractionated total 
lymphoid irradiation as preparation immunosuppression in high-risk 
renal transplantation. Ann Surg 1982; 196: 442-52. 
13 Kahn DR, Hong R, Greenberg AJ, Gilbert EF, Dacumos GC, Dufek 
JH. Total lymphatic irradiation and bone marrow in human heart 
transplantation. Ann Thorac Surg 1984; 38: 169-71. 
14 Myburgh JA, Meyers AM, Thomson PD, et at. Total lymphoid 
irradiation-current status. Transplant Proc 1989; 21: 826-28. 
15 Barber WH, Mankin JA, Laskow DA, et at. Long-term results ofa 
controlled prospective study with transfusion of donor specific bone 
marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 
51: 70-75. 
16 Rolles K, Burrough AK, Davidson BR, Karatapanis S, Prentice HG, 
Hamon MD. Donor-specific bone marrow infusion after orthotopic 
liver transplantation. Lancet 1994; 343: 263-65. 
17 Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in 
human renal homografts with subsequent development of homograft 
tolerance. Surg Gynecol Obstet 1963; 117: 385-95. 
18 Starzl TE, Demetris AJ, Murase N, Thomson A W, Trucco M, 
Ricordi C. Cell chimerism permitted by immunosuppressive drugs is 
the basis of organ transplant acceptance and tolerance. Immunol Today 
1993; 14: 326-32. 
19 Starzl TE, Demetris AJ, Rao AS, et al. Spontaneous and iatrogenically 
augmented leukocyte chimerism in organ transplant recipients. 
Transplant Proc (in press). 
155 
